Transcript File - Hypermedical Life Science and Technology, Inc.

Hypermed Inc. Uses of U.S.-Patented
safe Hyperthermia Technology to Treat
Cancers and AIDS
&
Background Science & Published
Academic Papers
US National Cancer Institute Info on
Hyperthermia in cancer treatment
Why Hyperthermia?
 Cancer cells and viruses can be significantly
reduced by heat, as in hyperthermia treatment.
This is a well-known biological fact.
 What has held back the use of hyperthermia to
treat cancer and viral infections such as AIDS is
the risk of damage to the brain.
 Hypermed, Inc. has developed a patented
technology to protect the brain to enable using
hyperthermia to be used safely in treating cancers,
AIDS and other infections.
Hypermed Inc. Has U.S. Patent on Brain Protection
 Patent #6669661: “Method and Device for
Central Nervous System Protection
During Whole Body Hyperthermia or
Hypothermia”, Inventor: Dr. Thomas Yee,
MD
 Established science: Heat can kill cancer
cells & viruses (HIV).
 Established science: Hypothermia can
preserve viability of organs.
 Up to now, whole-body hyperthermia is
not used due to fear of brain damage
 This patented technology makes it safe to
perform whole-body profound
hyperthermia to cure cancer and to cure
infections such as AIDS.
Market & Revenue Projection for Treating Cancers with
Hyperthermia
 500,000 people die from cancer every
year in the U.S. 1,000,000 more people
die in other affluent countries.
 Heat can kill cancer cells.
 Hypermed, Inc. has patented
technology enabling safe whole-body
hyperthermia used in conjunction with
chemo, radiation, immuno-therapy,
angiogenesis-inhibiting treatments to
cure cancers.
 If only 10% of those dying of cancer in
affluent world seek Hyperthermia
treatment, at $50,000, the potential
annual revenue is 7.5 Billion Dollars.
Market & Revenue Projection for Using Safe Whole-Body
Hyperthermia to Treat AIDS & other Infections
 In the US , there are more than 2
million people with HIV virus & AIDS.
World-wide, more than 8 million people
have HIV infection. Millions of people
die from flu & other infections yearly.
 Heat can kill HIV, other viruses, and
bacteria. Hypermed, Inc. has the US
Patent that enables safe administration
of whole body hyperthermia.
 If only 100,000 people per year seek
Hyperthermia treatment for AIDS and
other infections, at $50,000, potential
annual revenue is $5 Billion Dollars.
Venture Capital Funding Needed for our Safe
Whole-Body Hyperthermia Technology
To demonstrate the safety profile and efficacy of hyperthermia treatment,
Hypermed seeks 5 million dollars to complete animal study in the U.S.
and human study abroad.
1st Stage: Animal study using pigs at Utah Artificial Heart Institute
Subjects: 60 pigs
Time: 6 months
Cost: 2 million dollars
2nd Stage: Human study on young AIDS patients in Asia
Subjects: 50 young men with AIDS
Time: 6 months
Cost: 3 million dollars
Patent & Key Technology Abstract
 A method and device for intentionally inducing whole-body
hyperthermia or hypothermia in a patient for medical treatment
while protecting the central nervous system from damage
 A whole-body immersion chamber for temperature alteration. And
novel uses of existing FDA-approved pharmaceutical agents and
monitors to achieve profound brain metabolism reduction and
protection prior to temperature alteration or rapid detox challenge
 The patient's cerebral spinal fluid is circulated and maintained at
temperatures less drastically altered from normal temperatures by
a pump and a heater and cooler connected to the patient's spine
through catheters.
 The patient's central nervous system blood is separated from the
rest of the circulatory system and circulated and maintained at
temperatures less drastically altered from normal temperatures by
pumps and a heater and cooler. The remaining blood in the
patient's body is circulated and temperature controlled through
pumps and a heater and cooler.
Sites of Animal Research
UCSD Animal Research
Facility
University of California, San Diego
La Jolla, California
Utah Artificial Heart Institute
Salk Lake City, Utah
Development site of the Jarvik Artificial Heart
Published Journal Articles
Supporting Hypermed Inc.’s Basis for
Developing Technology in
Rapid Detox and in Hyperthermia
Treatment for Cancer
Supporting Published Journal
Papers on Hyperthermia:
Medical Journal: Annals of Oncology. 2002 Aug;13(8):1173-84.
Heating the patient: a promising approach?
van der Zee J.
Erasmus Medical Center-Daniel den Hoed Cancer Center, Department of
Radiation Oncology, Hyperthermia Unit, Rotterdam, The Netherlands
 The effects of both radiotherapy and many drugs are enhanced at an
increased temperature
 These findings justify using hyperthermia as part of standard treatment in
tumor sites for which its efficacy has been proven and, furthermore, to
initiate new studies with other tumors. Hyperthermia is certainly a promising
approach and deserves more attention than it has received until now.
US National Cancer Institute Info
Medical Journal: Perfusion. 2002 Jul;17(4):279-90.
Whole-body hyperthermia: a review of theory, design
and application.
Vertree RA, Leeth A, Girouard M, Roach JD, Zwischenberger JB.
Department of Surgery,
The University of Texas Medical Branch, Galveston
 All patients were safely heated to 42 or 42.5 degrees C for 2 h and
survived the 30-day study period
 Hyperthermia has been used successfully to treat isolated neoplastic
lesions of the head and neck, regional tumors such as melanoma of
the limb, and is under investigation as either an adjunct to, or therapy
for, locally disseminated and systemic diseases
Surgery. 2002 Jan;131(1 Suppl):S121-7.
Hyperthermia for rectal cancer.
Ohno S, Sumiyoshi Y, Mori M, Sugimachi K.
Department of Breast Surgery, National Kyushu Cancer Center, Fukuoka,
Japan.
Hyperthermia combined with radiation or chemotherapy
demonstrates great promise for the treatment of patients with carcinoma
of the rectum.
Cancer Immunology and Immunotherapy. 2002 Dec;51(11-12):603-13.
41.8 degrees C whole body hyperthermia as an adjunct to
chemotherapy induces prolonged T cell activation in patients
with various malignant diseases.
Atanackovic D, Nierhaus A, Neumeier M, Hossfeld DK, HegewischBecker S Department of Oncology and Hematology, University Clinic
Eppendorf, Hamburg, Germany
 This the first study to provide evidence for prolonged WBH-CTinduced activation of human T cells.
 Whole body hyperthermia (WBH) has been used as an adjunct to
radio-/chemotherapy in patients with various malignant diseases
Critical Review of Oncology and Hematology. 2002
Jul;43(1):33-56.
The cellular and molecular basis of hyperthermia.
Hildebrandt B, Wust P, Ahlers O, Dieing A,
Sreenivasa G, Kerner T, Felix R,
Medical Clinic, Department of Hematology and
Oncology, Charite Medical School, Humboldt-University,
Campus Virchow Clinic, D-13344 Berlin, Germany.
An improvement of both local control and survival rates
have been demonstrated by adding local/regional
hyperthermia to radiotherapy in patients with locally
advanced or recurrent superficial and pelvic tumors
European Journal of Cancer. 2001 Jul;37(11):1429-34.
Enhancement of the therapeutic outcome of radio-immunotherapy by
combination with whole-body mild hyperthermia.
Saga T, Sakahara H, Nakamoto Y, Sato N, Ishimori T, Mamede M,
Kobayashi H, Masunaga S, Sasai K, Kuroki M, Konishi J.
Department of Nuclear Medicine and Diagnostic Imaging, Graduate
School of Medicine, Kyoto, Japan.
The addition of whole-body mild hyperthermia significantly
enhanced the therapeutic effect of radio-immunotherapy by
increasing the radiosensitivity of the tumor.
International Journal of Hyperthermia. 2003 Jul-Aug;19(4):444-60.
Heat- and 4-hydroperoxy-ifosfamide-induced apoptosis in B cell
precursor leukaemias.
Mauz-Korholz C, Dietzsch S, Banning U, Trobs RB, Korholz D.
Department of Pediatrics, University of Leipzig Medical Center,
Oststr 21-25, D-04317 Leipzig, Germany
 Application of hyperthermia enhances efficacy of certain antineoplastic drugs such as ifosfamide
 whole body thermochemotherapy could be considered as a
treatment option in relapsed leukaemic patients.
Cancer Immunology and Immunotherapy. 2002 Dec;51(11-12):603-13.
41.8 degrees C whole body hyperthermia as an adjunct to
chemotherapy induces prolonged T cell activation in patients with
various malignant diseases.
Atanackovic D, Nierhaus A, Neumeier M, Hossfeld DK, HegewischBecker S Department of Oncology and Hematology, University Clinic
Eppendorf, Hamburg, Germany
 This the first study to provide evidence for prolonged WBH-CTinduced activation of human T cells.
 Whole body hyperthermia (WBH) has been used as an adjunct to
radio-/chemotherapy in patients with various malignant diseases